Table 2 Baseline characteristics of the study population (n = 19)
Characteristic | Value |
|---|---|
Age, years, median (range) | 60 (34–86) |
Performance status, n | |
 0 | 9 |
 1 | 9 |
 2 | 1 |
Measurable disease, n (%) | 16 (84) |
Prior therapy, n | |
 Chemotherapy | 17 |
 Hormonal therapy | 7 |
 HER-2 inhibitor | 18 |
 Radiotherapy | 15 |
ER-positive, n (%) | 10 (53%) |
HER-2 positive, n (%) | 19 (100%) |
Number of sites of disease, n (%) | |
 1 | 5 (26%) |
 2 | 2 (11%) |
 3 | 6 (32%) |
 ≥4 | 6 (32%) |
Site of disease, n (%) | |
 Bone | 9 (47%) |
 Soft tissue | 10 (53%) |
 Brain | 2 (11%) |
 Lung/liver | 16 (84%) |